Introduction
Cardiovascular disease (CVD) is a major cause of morbidity and mortality among patients with end-stage renal disease (ESRD). Mortality in dialysis patients is almost 10-20 times higher than in general population [1] . Although many traditional risk factors contribute to the development of CVD in ESRD patients, CVD is also associated with non-traditional risk factors such as mineral bone disease, and oxidative and inflammatory state [2] . Arterial stiffness, as reflected by an increase in pulse wave velocity (PWV), is an important predictor of cardiovascular mortality in dialysis patients [3] . Atherosclerosis of the arteries has traditionally been considered as a risk factor of CVD. However, compared with atheromatous change, sclerotic change of the arterial wall has only recently been studied. Arterial stiffness, a powerful independent predictor of allcause and cardiovascular mortality, can be examined by measurement of PWV [3] [4] [5] .
The recent Kidney Disease: Improving Global Outcome (KDIGO) has recommended a classification for mineral and bone disorder of chronic kidney disease (CKD-MBD) and an investigation of the relationship between radiologic vascular calcification assessment and measurement of vascular stiffness by PWV [6] . Vascular calcification is also very common and has been considered recently as an important predictor of mortality in dialysis patients [7] . Vascular calcification scores have been evaluated in haemodialysis (HD) patients by various methods [5, 8, 9] . Recently, simple vascular calcification score (SVCS), evaluated by plain X-ray of the pelvis and both hands, was a predictor of cardiovascular mortality and was associated with higher risk of coronary disease, peripheral artery disease and cardiovascular hospitalizations [10] . The presence of stimulators and inhibitors of the development of vascular calcification has been reported in experimental researches. Fetuin-A has been identified as a negative acute-phase reactant and is considered as one of the potent circulating calcification inhibitors [11] . In dialysis patients, lower fetuin-A level is associated with both higher prevalence of vascular calcification and cardiovascular mortality [12, 13] .
Arterial stiffness is associated with vascular calcification, and also, both can affect cardiovascular complications. Therefore, we hypothesized that fetuin-A, a vascular calcification inhibitor, may affect vascular calcification of the peritoneal dialysis (PD) patients and, in turn, may affect the aortic stiffness assessed by PWV. From our PD patients, we investigated the association of fetuin-A and other factors with aortic stiffness at baseline and with its change over time.
Materials and methods

Study design
This is a prospective, observational, single-centre study of a cohort of prevalent patients treated with PD. Studies were divided into two. In the first study, we investigated the relation among serum fetuin-A level, arterial stiffness and vascular calcification at baseline. In the second study, we evaluated the changes of PWV from the same patient population over 1 year and intended to elucidate factors associated with the change of PWV.
Subjects
We enrolled 72 consecutive PD patients visiting our PD unit at Seoul National University Hospital between July 2006 and December 2007. Patients were enrolled if they: (i) had been on PD for at least 3 months; (ii) agreed to participate in the study, which was approved by our Institutional Review Board; and (iii) were free of any complicating conditions to affect the serum fetuin-A level, such as underlying malignancy, infection, heart failure or liver disease. Five patients were lost during the follow-up period; three patients were transferred to other hospitals, and two patients received kidney transplantation. Finally, we analysed 67 patients (37 men and 30 women) who were examined both at baseline and after a 1-year follow-up. Sixty-four patients were treated with continuous ambulatory PD (CAPD, 4 × 2 L), with no attempt to change dialysis dose during a 1-year follow-up period. Three patients were treated with automated PD (APD).
Evaluation of aortic stiffness by PWV
Measurement of PWV was performed after a 5-min rest in a supine position in a quiet room. The PWV was measured by the automatic wave form analyser (VP-2000, Nippon Colin Ltd, Komaki City, Japan). Carotid and femoral arterial pressure waveforms were stored for 30 s by applanation tonometry sensors attached on the left common carotid and left common femoral arteries. Bilateral brachial and post-tibial arterial pressure waveforms were stored for 10 s by extremity cuffs connected to a plethysmographic sensor and an oscillometric pressure sensor wrapped on both arms and ankles. The electrocardiogram was monitored from electrodes on both wrists. Heart sound S1 and S2 were detected by a microphone on the left edge of the sternum at the third intercostal space. The waveform analyser measures time intervals between S2 and the notch of the carotid pulse wave (T hc ), and between the carotid and femoral artery pulse wave (T cf ). The sum of T hc and T cf gives the time required for pulse waves to travel from the heart (aortic orifice) to the femoral artery (T hf ). The heart-to-femoral PWV (hfPWV) was calculated from the following equation: L hf / (T hc + T cf ). L hf is the distance from the heart to the femoral artery. The distance between the sampling points and L hf is automatically calculated from the patient height, and was divided by the time interval for the wave form from each measuring point [14, 15] . hfPWV, a central stiffness index, are being used as arterial stiffness markers due to ease of measurement, reproducibility and validity in previous studies [16] . hfPWV was assessed for all patients both at baseline and at 1 year.
Biochemical analysis
In the first study, the parameters examined included age, mean blood pressure, body mass index (BMI), the duration of dialysis in months, residual renal function, total weekly Kt/V, smoking status, atherosclerotic vascular disease history and medication history. Other parameters that were measured, using standard laboratory techniques, included haemoglobin, calcium (Ca), phosphorus (P), the calcium-phosphate product (Ca × P), intact parathyroid hormone (iPTH), total cholesterol (TC), triglyceride (TG), albumin and highly sensitive C-reactive protein (hsCRP). Correlations of hfPWV with serum fetuin-A level and other parameters were studied. In the second study, blood pressure and biochemical parameters were measured every 3 months during the follow-up, and annual time-averaged values were calculated. For each patient, after blood sampling, the samples were allowed to clot at room temperature, and were centrifuged at 3000 rpm for 15 mins. The sera were harvested and stored at −70°C until analysis. Fetuin-A was measured from 1:10000 diluted serum by means of a human enzyme-linked immunosorbent assay (ELISA) kit (RD191037100R, Biovendor, Czech Republic). The assay utilizes a two-site sandwich technique with two selected polyclonal antibodies that bind to different epitopes of human fetuin-A. Intra-and inter-assay coefficients of variation were 4.7% and 7.2%, respectively.
Vascular calcification
Vascular calcifications were evaluated at baseline by a single observer blind to clinical data, in a plain radiograph of the pelvis and the both hands by a method previously reported [10] . In brief, the pelvis radiographic films were divided into four sections by two imaginary lines: a horizontal line over the upper limit of both femoral heads and a median vertical line over the vertebral column. The films of the hands were divided, for each hand, by a horizontal line over the upper limit of the metacarpal bones. The presence of linear calcifications in each section was counted as 1 and its absence as 0. The final score was the sum of all the sections, ranging from 0 to 8.
Statistical analysis
Continuous variables were tested for normality with the KolmogorovSmirnov test before further statistical analysis. Variables without a normal distribution were either transformed into a logarithmic scale and then subjected to parametric tests, or analysed by a non-parametric test. Values with normal distribution are expressed as mean ± standard deviation, while those without normal distribution were shown as median and interquartile range. Comparison between two groups was performed with unpaired Student's t-test. Correlation between two continuous variables was analysed by Pearson's correlation test. Multiple linear regression analysis was performed to examine the factors related to the baseline PWV and the change of PWV (ΔPWV) over 1 year. At all the statistical analysis, P < 0.05 was considered statistically significant. SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis.
Results
The clinical characteristics of study patients are shown in Table 1 . Their age was 50 ± 14 years, and time on PD was 26 (interquartile range, 5-58) months. The causes of ESRD were diabetes (35.8%), primary or secondary glomerulonephritis (21%), hypertensive nephropathy (11.9%), and polycystic kidney disease (1.5%). At baseline, 76.1% of the patients were taking antihypertensive therapy-i.e. angiotensin-converting enzyme inhibitors, beta-blockers or dihydropyridine calcium channel blockers given in monotherapy or in combinations-and 89.6% of the patients were receiving phosphorus-lowering agents such as calcium-based phosphate binder or sevelamer. Their oral medications were continued during follow-up.
First study: fetuin-A as one of predictors of aortic stiffness in peritoneal dialysis Table 2 shows the biochemical parameters at inclusion. Serum fetuin-A concentration was 0.34 ± 0.08 g/L, and hfPWV was 1022 ± 276 cm/s. In our PD patients, fetuin-A significantly and inversely correlated with hfPWV (r = −0.316, P = 0.012; Figure 1A ). SVCS positively correlated with hfPWV (r = 0.433, P = 0.003). Patients with SVCS ≥2, when compared with patients with SVCS <2, had lower serum fetuin-A concentration (0.28 ± 0.08 vs. 0.35 ± 0.07 g/L, P = 0.026; Figure 1B ) and higher hfPWV (1226 ± 309 vs. 962 ± 223 cm/s, P = 0.005; Figure 1C ). In univariate analysis, aortic PWV positively correlated with age, smoking status, diabetes, MAP, total cholesterol and LDL cholesterol. On the other hand, it negatively correlated with fetuin-A, log PTH, haemoglobin and albumin ( Figure 1 , Table 3 ). In a multiple regression model, serum fetuin-A remained as an independent determinant of aortic PWV after adjustment for age, MAP, diabetes and albumin (Table 4) . Age, MAP and log PTH were also determinants of aortic stiffness in our PD patients.
Second study: ΔMAP and aTG are predictors of change of aortic stiffness in peritoneal dialysis hfPWV determined 1 year after baseline was 1069 ± 317 cm/s. ΔhfPWV was 44 ± 209 cm/s. We observed that some patients showed 15% (median of annual increasing change of hfPWV) or more increase in hfPWV from the baseline (progressors). Clinical data for the progressors were compared with those of the patients not classified as a progressor (non-progressors). Patient profiles for the progressors and non-progressors are summarized in Table 5 . There were 21 progressors and 46 non-progressors. At baseline, age, smoking status and diabetes prevalence were relatively high in progressors. For each group, the changes in hfPWV showed significant correlations with changes in both systolic and diastolic blood pressures despite similar baseline values. Laboratory parameters during the follow-up period such as time-averaged HDL (aHDL) and time-averaged TG (aTG) were different between the ADPKD, autosomal dominant polycystic kidney disease; LVM, left ventricular mass; ASVD, atherosclerotic vascular disease; hfPWV, heart-tofemoral pulse wave velocity at baseline; hfPWV-1, hfPWV at 1-year; ΔhfPWV, difference between 1-year PWV and baseline PWV; RAS, renin-angiotensin system. a Median, interquartile range.
Aortic stiffness in PD patientstwo groups. Progressors had higher aTG and lower aHDL, compared with non-progressors. In univariate analysis (Supplementary Table 1) , ΔhfPWV positively correlated with MAP estimated 1 year after baseline (r = 0.469, P < 0.001) and changes of MAP over time (r = 0.566, P < 0.001, Figure 2B ). As shown in Figure 2A , the finding from the second study showed that the changes in ΔhfPWV were related to the average value of TG levels exposed during the 1-year observation period. In addition, time-averaged peritoneal ultrafiltration volume was inversely related with ΔhfPWV (r = −0.286, P = 0.025).
In a multiple regression model, ΔMAP and time-averaged TG were independent determinants of ΔhfPWV ( Table 6 ).
Discussion
Fetuin-A has been reported to be related to arterial stiffness [2, 17] , as well as with increased cardiovascular and allcause mortality [12, 18] . In our study as well, it was ob- 0.34 ± 0.08 served that the level of serum fetuin-A was an independent predictor of aortic stiffness at baseline. Until now, various authors have shown that serum fetuin-A level was associated with arterial stiffness in cross-sectional analysis.
In the present study, we also evaluated whether the baseline serum fetuin-A level could affect the changes of hfPWV from the same patient population over 1 year and intended to elucidate factors associated with the change of hfPWV. Although 1 year is not sufficient enough to observe the change of aortic stiffness, a subgroup of patients exhibited >15% increase of PWV during this period. ΔMAP and time-averaged TG were independent determinants of ΔhfPWV. However, in our study, baseline fetuin-A concentration was not associated with the change of PWV over time. Arterial stiffness has been evaluated by measuring the PWV using the tonometric sensor on the carotid and femoral arteries. Increased aortic stiffness was associated with age, Adjusted by diabetes, SVCS, ASVD history, gender, smoking history, BSA, albumin and haemoglobin. Beta, unstandardized coefficient; hfPWV, heart-to-femoral pulse wave velocity; MAP, mean arterial pressure; SVCS, simple vascular calcification score; ASVD, atherosclerotic vascular disease; BSA, body surface area. 3.6 ± 0. hypertension, diabetes and ESRD. Aortic stiffness was well established as an independent predictor of all-cause and cardiovascular mortality in the general population as well as in ESRD patients [3, 5] . Carotid-to-femoral PWV (cfPWV) reflects aortic PWV. However, this parameter has low reproducibility because of technical difficulty. Currently, hfPWV and brachial-to-ankle PWV (baPWV) are automatically measured by the oscillometric technique using blood pressure cuffs over arms and ankles, which are simple and reproducible as compared with the cfPWV measurement. While hfPWV assesses the stiffness of large and central arteries such as the aorta, baPWV reflects both the central and peripheral arteries [15, 19] . Therefore, it is reasonable that hfPWV, rather than baPWV, can substitute for cfPWV in the measurement of the aortic stiffness. There are numerous reports on a good correspondence between functional and structural assessment of vascular stiffness in HD patients [3, [20] [21] [22] [23] . The association between aortic PWV and coronary artery calcification suggests that aortic PWV is a marker for the development of atherosclerotic coronary artery disease, as proposed in the general population and HD patients [23] . In ESRD patients on PD, a few studies have investigated the factors associated with hfPWV. Our study showed that hfPWV was associated with age, male gender, smoking habit, history of atherosclerotic vascular disease (ASVD), diabetes, MAP, TC, LDL-C, albumin, haemoglobin and log PTH, which was similar with previous reports from HD patients [22] .
Fetuin-A, a 62-kDa glycoprotein, is synthesized by liver cells and exists in the extracellular fluid at a blood concentration of 0.5-1.0 g/L; it exerts strong inhibition of ectopic calcification by inhibiting hydroxyapatite formation, with the induction of transforming growth factor-β action, and insulin receptor tyrosine kinase. Fetuin-A has been reported to be related to the MIA (malnutrition, inflammation and atherosclerosis) syndrome and the survival of dialysis patients [2, 11, 12] . Stenvinkel et al. reported that low fetuin-A levels were associated with malnutrition, inflammation and atherosclerosis, as well as with increased cardiovascular and all-cause mortality [18] . In the present study, we hypothesized that fetuin-A, as an inhibitor of vascular calcification, may affect vascular calcification from our PD patients and, subsequently, may affect the aortic stiffness. Our study showed for the first time from adult PD patients that the serum levels of fetuin-A inversely and independently correlated with hfPWV. The correlation remained significant after adjustment for age, gender, MAP and diabetes. It also showed that serum fetuin-A concentration was associated with the SVCS. SVCS, in turn, was associated with hfPWV in the present study. As a result, low serum fetuin-A concentration was associated with higher hfPWV in our dialysis patients.
In contrast, Hermans et al. reported that fetuin-A levels were inversely related to PWV; however, after correction for covariates, this relation lost statistical significance [17] . From the above report, serum fetuin-A concentration is relatively high in dialysis patients compared with healthy controls. This is not consistent with other reports that dialysis patients have low serum fetuin-A level compared with healthy controls [24] . In the previous study by Ketteler et al., mean fetuin-A levels in HD patients were lower than healthy controls (0.66 vs. 0.72 g/L; P = 0.014) [12] . Compared with our results, the serum fetuin-A level Our study showed an absence of a relation between the baseline serum fetuin-A levels and the changes of hfPWV over a 1-year observation. Ford et al. [25] , on the other hand, showed that fetuin-A is an independent risk factor for change in arterial stiffness in non-diabetic patients with CKD stages 3 and 4. However, compared with our study, they only analysed the association of baseline parameters with change in PWV, and not the time-averaged parameters, so it needs adjustment with other related parameters not to overestimate the effect of fetuin-A.
In this study, we also assessed the PWV at 1 year. To our knowledge, this is the first report from a longitudinal observation for over-time change of the aortic stiffness in PD patients. ΔhfPWV was related with changes of blood pressure (ΔSBP, ΔDBP, ΔMAP and ΔPP). Hypertension is a strong risk factor for cardiovascular disease. Blacher et al. [4] showed that aortic PWV correlated with systolic blood pressure in ESRD patients. In the present study, we showed significant relationship between blood pressure and changes in hfPWV. In the previous study by Takenaka et al. [26] , they observed no relationship between blood pressure and changes in PWV from HD patients. However, they measured PWV after HD sessions when the patients reached their own dry weights. This could have masked the relationship between the blood pressure and change of PWV.
Our results also indicate that increments in hfPWV correlated positively with time-averaged value of TG level (aTG). This is similar to the result by Takenaka et al. [26] . Shoji et al. [27] reported that, in HD patients, intermediate density lipoprotein cholesterol, which contained cholesterol and TG, was an independent risk factor of atherosclerosis. Relations between hypertriglyceridaemia and atherosclerosis have been controversial. Lundman et al. [28] reported that chronic hypertriglyceridaemia results in endothelial dysfunction, possibly due to increased plasma asymmetric dimethylarginine (ADMA) concentration, which is an endogenous nitric oxide synthase inhibitor. They also reported that transient hypertriglyceridaemia induced by infusion of a TG emulsion (Intralipid ® ) resulted in decreased flow-mediated vasodilation [29] . Indeed, multivariate stepwise regression revealed that aTG correlated strongly with an increase in hfPWV in the present study. It needs to be seen in the future whether control of adequate TG level may prevent progression of aortic stiffness in PD patients.
To summarize, the present study showed that fetuin-A, along with age, MAP and intact PTH, is independently associated with hfPWV from PD patients. The mean value of change in hfPWV over 1 year was not serious. However, we observed that some patients showed 15% or more increase in hfPWV from the baseline (progressors). ΔMAP and time-averaged TG were independent determinants of 1-year changes in aortic stiffness. Our study showed an absence of a relation between the baseline serum fetuin-A levels and the changes of hfPWV over a 1-year observation.
Interpreting the absence of such a potential independent influence of fetuin-A on the changes of hfPWV, this is a small numbered study, and it is important to point out that MAP are the major predictors of change of aortic stiffness overriding its association with fetuin-A. Larger scaled and prospective studies over longer periods are warranted to investigate whether control of the blood pressure and TG might result in reduction of the aortic stiffness.
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